Die Umsatzanteile sind Schätzungen für quarter ended 2026-03-31 und keine Zahlen aus einem eingereichten Bericht.
Established Pharmaceutical Products
Branded generic medicines sold outside the United States, including treatments for digestive conditions, women's health, heart and metabolic conditions, pain, and respiratory infections.
Diagnostic systems and tests
Laboratory instruments, test kits, and rapid tests used to help detect or monitor conditions such as infections, cancer, heart problems, and thyroid disorders.
Nutrition products
Infant formula, adult nutrition drinks and powders, and products used for feeding patients in healthcare institutions, including Similac, Ensure, and PediaSure.
Heart and other medical devices
Products include pacemakers, heart valves, devices used to treat narrowed blood vessels, and implanted devices for chronic pain or movement disorders.
FreeStyle Libre
A continuous glucose monitoring system with a sensor worn on the body to measure glucose levels for people with diabetes.
Cologuard
A stool-based test used to screen for colorectal cancer; Abbott discussed it on its earnings call as part of its cancer diagnostics business.
Abbott develops, makes, and sells healthcare products around the world. Its businesses include branded generic medicines sold outside the United States, diagnostic tests and equipment, nutrition products, and devices for heart conditions, diabetes, and other needs. Its buyers include healthcare providers, distributors, retailers, government agencies, and consumers.
Gebaut aus den eigenen Einreichungen von Abbott Laboratories bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.
The themes Abbott Laboratories is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
107,27 $-1,9 %Schluss 12. Nov.
Zahlen bis 30. September 2026, aus dem 10-Q vom 4. November 2026
Abbott makes and sells medicines, diagnostic tests, nutrition products, and medical devices.
Grade B
Das Band unter dem Kurs zeigt die Note an jedem Tag – gebildet nur aus den Unterlagen, die bis dahin veröffentlicht waren.
Zeigt 2 von 40 Quartalen der Notenhistorie von Abbott Laboratories. Die übrigen 38 reichen zurück bis November 2016.
